Last reviewed · How we verify

Besifloxacin Ophthalmic Suspension 0.6%

Bausch & Lomb Incorporated · Phase 1 active Small molecule

Besifloxacin Ophthalmic Suspension 0.6% is a Small molecule drug developed by Bausch & Lomb Incorporated. It is currently in Phase 1 development. Also known as: ISV-403.

At a glance

Generic nameBesifloxacin Ophthalmic Suspension 0.6%
Also known asISV-403
SponsorBausch & Lomb Incorporated
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Besifloxacin Ophthalmic Suspension 0.6%

What is Besifloxacin Ophthalmic Suspension 0.6%?

Besifloxacin Ophthalmic Suspension 0.6% is a Small molecule drug developed by Bausch & Lomb Incorporated.

Who makes Besifloxacin Ophthalmic Suspension 0.6%?

Besifloxacin Ophthalmic Suspension 0.6% is developed by Bausch & Lomb Incorporated (see full Bausch & Lomb Incorporated pipeline at /company/bausch-lomb-incorporated).

Is Besifloxacin Ophthalmic Suspension 0.6% also known as anything else?

Besifloxacin Ophthalmic Suspension 0.6% is also known as ISV-403.

What development phase is Besifloxacin Ophthalmic Suspension 0.6% in?

Besifloxacin Ophthalmic Suspension 0.6% is in Phase 1.

Related